Literature DB >> 29696633

Generation of reporter hESCs by targeting EGFP at the CD144 locus to facilitate the endothelial differentiation.

Zhiqing Hu1, Yong Wu1, Miaojin Zhou1, Xiaolin Wang1, Jialun Pang1, Zhuo Li1, Mai Feng1, Yanchi Wang1, Qian Hu1, Junya Zhao1, Xionghao Liu1, Lingqian Wu1, Desheng Liang1.   

Abstract

Reporter embryonic stem cell (ESC) lines with tissue-specific reporter genes may contribute to optimizing the differentiation conditions in vitro as well as trafficking transplanted cells in vivo. To optimize and monitor endothelial cell (EC) differentiation specifically, here we targeted the enhanced green fluorescent protein (EGFP) reporter gene at the junction of 5'UTR and exon2 of the endothelial specific marker gene CD144 using TALENs in human ESCs (H9) to generate a EGFP-CD144-reporter ESC line. The reporter cells expressed EGFP and CD144 increasingly and specifically without unexpected effects during the EC differentiation. The EC differentiation protocol was optimized and applied to EC differentiation from hiPSCs, resulting in an efficient and simplified endothelial differentiation approach. Here we created our own optimized and robust protocol for EC differentiation of hESCs and hiPSCs by generating the lineage-specific site-specific integration reporter cell lines, showing great potential to be applied in the fields such as trafficking gene and cell fate in vivo in preclinical animal models.
© 2018 Japanese Society of Developmental Biologists.

Entities:  

Keywords:  CD144; endothelial differentiation; enhanced green fluorescent protein reporter; gene editing; transcription activator-like effector nucleases

Mesh:

Substances:

Year:  2018        PMID: 29696633     DOI: 10.1111/dgd.12433

Source DB:  PubMed          Journal:  Dev Growth Differ        ISSN: 0012-1592            Impact factor:   2.053


  1 in total

Review 1.  Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity.

Authors:  Chengyi Tu; Nathan J Cunningham; Mao Zhang; Joseph C Wu
Journal:  Front Pharmacol       Date:  2021-03-10       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.